Brucellosis laboratory findings: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Removing from Primary care)
 
(12 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Brucellosis}}
{{Brucellosis}}
{{CMG}}; {{AE}} {{RT}} {{DL}}
{{CMG}}; {{AE}} {{RT}} {{DL}}{{VD}}


==Overview==
==Overview==
The diagnosis of brucellosis can be confirmed by either a positive bacterial culture or a positive titer of anti-[[Brucella|''Brucella'']] antibodies on serological testing.<ref name="e">Brucellosis 2010 Case Definition. CDC. http://wwwn.cdc.gov/nndss/conditions/brucellosis/case-definition/2010/. Accessed on February 2, 2016</ref>
The diagnosis of brucellosis can be confirmed by either a positive [[Bacterial cultures|bacterial culture]] or a positive titer of anti-[[Brucella|b''rucella'']] [[antibodies]] on serological testing.


==Laboratory Findings==
==Laboratory Findings==
Laboratory findings of brucellosis include the following:<ref name="g" /><ref name=":0">Brucellosis "Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson, Joseph Loscalzo"Harrison's Principles of Internal Medicine, 19e Accessed on December 9th, 2017</ref><ref>Colmenero JD, Reguera JM, Martos F, Sánchez-De-Mora D, Delgado M, Causse M; et al. (1996). [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8699960 "Complications associated with Brucella melitensis infection: a study of 530 cases."]. ''Medicine (Baltimore)''. '''75''' (4): 195–211. PMID [http://www.ncbi.nlm.nih.gov/pubmed/8699960 8699960]</ref><ref name=":1">Mantur BG, Amarnath SK, Shinde RS (2007). [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17901634 "Review of clinical and laboratory features of human brucellosis."]. ''Indian J Med Microbiol''. '''25''' (3): 188–202. PMID [http://www.ncbi.nlm.nih.gov/pubmed/17901634 17901634]</ref><ref>Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15930423 "Brucellosis."]. ''N Engl J Med''. '''352''' (22): 2325–36. PMID [http://www.ncbi.nlm.nih.gov/pubmed/15930423 15930423].</ref><ref name="pmid23236528">{{cite journal| author=Dean AS, Crump L, Greter H, Hattendorf J, Schelling E, Zinsstag J| title=Clinical manifestations of human brucellosis: a systematic review and meta-analysis. | journal=PLoS Negl Trop Dis | year= 2012 | volume= 6 | issue= 12 | pages= e1929 | pmid=23236528 | doi=10.1371/journal.pntd.0001929 | pmc=3516581 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23236528  }}</ref><ref>Young EJ (1995). [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7546364 "Brucellosis: current epidemiology, diagnosis, and management."]. ''Curr Clin Top Infect Dis''. '''15''': 115–28. PMID [http://www.ncbi.nlm.nih.gov/pubmed/7546364 7546364]</ref><ref>Aygen B, Doganay M, Sumerkan B, et al. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med Malad Infect 2002; 32:485.</ref><ref name="pmid21623056">{{cite journal| author=Zamani A, Kooraki S, Mohazab RA, Zamani N, Matloob R, Hayatbakhsh MR et al.| title=Epidemiological and clinical features of Brucella arthritis in 24 children. | journal=Ann Saudi Med | year= 2011 | volume= 31 | issue= 3 | pages= 270-3 | pmid=21623056 | doi=10.4103/0256-4947.81543 | pmc=3119967 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21623056  }}</ref><ref>Mousa AM, Bahar RH, Araj GF, Koshy TS, Muhtaseb SA, al-Mudallal DS; et al. (1990). [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2330811 "Neurological complications of brucella spondylitis."]. ''Acta Neurol Scand''. '''81''' (1): 16–23. PMID [http://www.ncbi.nlm.nih.gov/pubmed/2330811 2330811]</ref><ref>Pappas G, Bosilkovski M, Akritidis N, Mastora M, Krteva L, Tsianos E (2003). [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13130417 "Brucellosis and the respiratory system."]. ''Clin Infect Dis''. '''37''' (7): e95–9. PMID [http://www.ncbi.nlm.nih.gov/pubmed/13130417 13130417]. [[Digital object identifier|doi]]:[http://dx.doi.org/10.1086%2F378125 10.1086/378125]</ref><ref>Herrick JA, Lederman RJ, Sullivan B, et al. Brucella arteritis: clinical manifestations, treatment, and prognosis. Lancet Infect Dis 2014; 14:520.</ref><ref name="pmid18162038">{{cite journal| author=Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME et al.| title=Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. | journal=PLoS Med | year= 2007 | volume= 4 | issue= 12 | pages= e317 | pmid=18162038 | doi=10.1371/journal.pmed.0040317 | pmc=2222927 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18162038  }}</ref>
{| class="wikitable"
{| class="wikitable"
!
! colspan="3" |Laboratory findings in Brucellosis
! colspan="2" |
|-
|-
| rowspan="5" |Blood  
| rowspan="7" |Blood  
|Complete blood count
|[[Complete blood count]]
|Complete Blood Count
|Complete [[Blood]] Count may reveal:
*Mild [[leukopenia]]
*Mild [[leukopenia]]
*Mild [[anemia]]  
*Mild [[anemia]]  
Line 19: Line 19:
*[[Thrombocytopenia]]
*[[Thrombocytopenia]]
|-
|-
|Liver function test
|[[Erythrocyte sedimentation rate|ESR]]
|Liver Function Tests
|Normal or raised
*Mild transaminasemia<ref name="pmid15930423">{{cite journal| author=Pappas G, Akritidis N, Bosilkovski M, Tsianos E| title=Brucellosis. | journal=N Engl J Med | year= 2005 | volume= 352 | issue= 22 | pages= 2325-36 | pmid=15930423 | doi=10.1056/NEJMra050570 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15930423 }} </ref><ref name="b">Brucellosis. CDC. http://www.cdc.gov/brucellosis/transmission/index.html. Accessed on February 1, 2016</ref>
|-
|[[CRP]]
|Normal or raised
|-
|[[Liver function tests|Liver function test]]
|Liver function test may reveal:
*Mild increase in [[hepatic]] [[enzymes]]  
*Mild increase in [[bilirubin]]
|-
|-
|Culture  
|Culture  
|
|
*The isolation and identification of [[Brucella|''Brucella'']] can confirm a diagnosis of brucellosis.  
*The isolation and identification of [[Brucella|''Brucella'']] can confirm a diagnosis of brucellosis.  
*[[Brucella|''Brucella'']] is most commonly isolated from blood cultures(blood cultures are positive between the 7th and 21st day)
*[[Brucella|''Brucella'']] is most commonly isolated from blood cultures (blood cultures are positive between the 7th and 21st day)
*It can also, however, be isolated from:
*It can also, however, be isolated from:
**[[Bone marrow]] ([[gold standard (test)|Gold standard test]])
**[[Bone marrow]] ([[gold standard (test)|Gold standard test]])
**[[Cerebrospinal fluid]]
**[[Cerebrospinal fluid]]
**Wounds
**[[Wounds]]
**[[Purulent]] [[discharge]]
**[[Purulent]] [[discharge]]
**[[Synovial fluid|Joint fluid]]<ref name="pmid15930423" /><ref name="g">Brucellosis. CDC. http://www.cdc.gov/brucellosis/clinicians/bacterial-isolation.html. Accessed on February 4, 2016</ref>
**[[Synovial fluid|Joint fluid]]<ref name="pmid15930423">{{cite journal| author=Pappas G, Akritidis N, Bosilkovski M, Tsianos E| title=Brucellosis. | journal=N Engl J Med | year= 2005 | volume= 352 | issue= 22 | pages= 2325-36 | pmid=15930423 | doi=10.1056/NEJMra050570 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15930423  }} </ref><ref name="g">Brucellosis. CDC. http://www.cdc.gov/brucellosis/clinicians/bacterial-isolation.html. Accessed on February 4, 2016</ref>
|-
|-
|Serological tests
|Serological tests
|Serological Tests
|Serological Tests
*'''There are two types of serological tests, based on:'''
*'''There are two types of serological tests, based on:'''
**Antibody production against lipopolysaccharide
**Antibody production against [[lipopolysaccharide]]
**Antibody production against other bacterial antigens
**Antibody production against other [[bacterial]] [[antigens]]
*'''For a diagnosis to be made using serology, two serum samples are required:'''
*'''For a diagnosis to be made using serology, two serum samples are required:'''
**The first serum sample should be taken when a person is acutely ill (≤7 days after symptom onset)
**The first [[serum]] sample should be taken when a person is acutely ill (≤7 days after symptom onset)
**The second serum sample should be drawn 2-4 weeks later to check for a rise in antibodies (a fourfold or greater rise in antibodies would bean an individual is positive for brucellosis).
**The second serum sample should be drawn 2-4 weeks later to check for a rise in [[antibodies]] (a fourfold or greater rise in antibodies would bean an individual is positive for brucellosis).
**If submission of paired sera is not possible, a probable diagnosis can be made with a single serum sample.
**If submission of paired sera is not possible, a probable diagnosis can be made with a single serum sample.
*'''Brucella microagglutination test (BMAT)'''  
*'''Brucella microagglutination test (BMAT)'''  
**A modified version of the serum (tube) agglutination test (SAT), that can detect antibodies to [[Brucella|''Brucella'']] species: [[Brucella abortus|abortus]], [[Brucella melitensis|melitensis]] or suis.  
**A modified version of the serum (tube) agglutination test (SAT), that can detect antibodies to [[Brucella|''Brucella'']] species: [[Brucella abortus|abortus]], [[Brucella melitensis|melitensis]] or suis.  
**There is no serological test available to detect antibodies to [[Brucella canis|''B. canis'']].
**There is no [[Serological testing|serological test]] available to detect [[antibodies]] to [[Brucella canis|''B. canis'']].
**An '''''agglutination''''' '''''titre greater than 1:160''''' is considered '''significant in nonendemic areas'''.
**An '''''agglutination''''' '''''titre greater than 1:160''''' is considered '''significant in nonendemic areas'''.
**An '''''agglutination''''' '''''titre greater than 1:320''''' is considered '''significant in endemic areas'''.
**An '''''agglutination''''' '''''titre greater than 1:320''''' is considered '''significant in endemic areas'''.
**Due to the similarity of the O polysaccharide of [[Brucella|''Brucella'']] to that of various other Gram-negative bacteria (e.g. [[Francisella tularensis]], [[Escherichia coli]], Salmonella urbana, [[Yersinia enterocolitica]], [[Vibrio cholerae]], and [[Stenotrophomonas maltophilia]]) the appearance of cross-reactions of class [[Immunoglobulin M|M immunoglobulins]] may occur.
**Due to the similarity of the O [[polysaccharide]] of [[Brucella|''Brucella'']] to that of various other [[gram-negative bacteria]] (e.g. [[Francisella tularensis]], [[Escherichia coli]], Salmonella urbana, [[Yersinia enterocolitica]], [[Vibrio cholerae]], and [[Stenotrophomonas maltophilia]]) the appearance of cross-reactions of class [[Immunoglobulin M|M immunoglobulins]] may occur.
**False-negative SAT may be caused by the presence of blocking antibodies (the prozone phenomenon) in the α2-globulin ([[IgA]]) and in the α-globulin ([[IgG]]) fractions.
**False-negative SAT may be caused by the presence of blocking [[antibodies]] (the prozone phenomenon) in the α2-globulin ([[IgA]]) and in the α-globulin ([[IgG]]) fractions.
**Serology is not currently available to monitor persons for RB51 vaccine exposure or for [[Brucella canis|''Brucella canis'']] exposure.
**[[Serology]] is not currently available to monitor persons for RB51 vaccine exposure or for [[Brucella canis|''Brucella canis'']] exposure.
*'''Rose Bengal'''
*'''Rose Bengal'''
**Rose bengal has a positive predictive value is approximately 99% for patients with acute and chronic brucellosis.
**Rose bengal has a positive predictive value is approximately 99% for patients with acute and chronic brucellosis.
**Rose bengal measures [[IgM]] and [[IgG]] antibodies.
**Rose bengal measures [[IgM]] and [[IgG]] antibodies.
*'''2-mercaptoethanol (2-ME)'''
*'''2-mercaptoethanol (2-ME)'''
**2-ME measures [[IgG]] antibodies
**2-ME measures [[IgG]] [[antibodies]]
*'''Antihuman globulin (Coombs)'''
*'''Antihuman globulin (Coombs)'''
**Used in chronic brucellosis patients with negative seroagglutination because they have [[IgG]] non-agglutinating antibodies.
**Used in chronic brucellosis patients with negative seroagglutination because they have [[IgG]] non-agglutinating antibodies.
*'''Indirect enzyme linked immunosorbent assay (ELISA)'''
*'''Indirect enzyme linked immunosorbent assay (ELISA)'''
**[[ELISA test|ELISA]] typically uses cytoplasmic proteins as antigens.  
**[[ELISA test|ELISA]] typically uses cytoplasmic [[proteins]] as [[antigens]].  
**[[ELISA test|ELISA]] measures [[IgM]], [[IgG]], and [[IgA]] with better [[Sensitivity (tests)|sensitivity]] and [[Specificity (tests)|specificity]] than the SAT in most recent comparative studies.
**[[ELISA test|ELISA]] measures [[IgM]], [[IgG]], and [[IgA]] with better [[Sensitivity (tests)|sensitivity]] and [[Specificity (tests)|specificity]] than the SAT in most recent comparative studies.
*'''Dipstick assays'''  
*'''Dipstick assays'''  
**New and promising, based on the binding of [[Brucella|''Brucella'']] [[IgM]] antibodies, and found to be simple, accurate, and rapid.
**New and promising, based on the binding of [[Brucella|''Brucella'']] [[IgM]] [[antibodies]], and found to be simple, accurate and rapid.
*'''Brucellacapt test'''  
*'''Brucellacapt test'''  
**A single-step immunocapture assay for the detection of total anti-[[Brucella|''Brucella'']] antibodies, is an increasingly used adjunctive test when resources permit.
**A single-step immunocapture assay for the detection of total anti-[[Brucella|''Brucella'']] antibodies, is an increasingly used adjunctive test when resources permit.
Line 68: Line 75:
|Molecular tests  
|Molecular tests  
|'''PCR'''
|'''PCR'''
*PCR is a fast and specific diagnostic tool to confirm the diagnosis of brucellosis  
*[[PCR]] is a fast and specific diagnostic tool to confirm the diagnosis of brucellosis  
*Many varieties of [[PCR]] have been developed (e.g. nested [[PCR]], realtime [[PCR]] and [[PCR]]-[[ELISA test|ELISA]]) and found to have superior [[Specificity (tests)|specificity]] and [[Sensitivity (tests)|sensitivity]] in detecting both primary infection and relapse after treatment.  
*Many varieties of [[PCR]] have been developed (e.g. nested [[PCR]], realtime [[PCR]] and [[PCR]]-[[ELISA test|ELISA]]) and found to have superior [[Specificity (tests)|specificity]] and [[Sensitivity (tests)|sensitivity]] in detecting both primary infection and relapse after treatment.  
*Unfortunately, these have yet to be standardized for routine use, and some centres have reported persistent [[PCR]] positivity after clinically successful treatment, fuelling the controversy about the existence of prolonged [[Chronic (medicine)|chronic]] brucellosis.<ref name="pmid15930423" /><ref name="b" /><ref name="a">Brucellosis. Wikipedia. https://en.wikipedia.org/wiki/Brucellosis. Accessed on January 29, 2016</ref><ref name="aa">Brucelosis. Wikipedia. https://es.wikipedia.org/wiki/Brucelosis. Accessed on February 2, 2016</ref>
*Unfortunately, these have yet to be standardized for routine use, and some centres have reported persistent [[PCR]] positivity after clinically successful treatment, fuelling the controversy about the existence of prolonged [[Chronic (medicine)|chronic]] brucellosis.<ref name="pmid15930423" /><ref name="b">Brucellosis. CDC. http://www.cdc.gov/brucellosis/transmission/index.html. Accessed on February 1, 2016</ref><ref name="a">Brucellosis. Wikipedia. https://en.wikipedia.org/wiki/Brucellosis. Accessed on January 29, 2016</ref><ref name="aa">Brucelosis. Wikipedia. https://es.wikipedia.org/wiki/Brucelosis. Accessed on February 2, 2016</ref>
|-
|}
|Synovial fluid
 
| colspan="2" |In patients presenting with brucella arthritis, lymphocytic predominate, WBC count does not generally exceed 15,000 cells/microL, which is similar to findings with reactive arthritis
==== Tissue Biopsy ====
[[Liver]] and [[lymph node]] biopsy may reveal non-[[Caseous necrosis|caseating]] [[granuloma]].<ref name=":0" /><ref name=":1" />


|}
==== CSF analysis ====
[[CSF analysis]] may reveal [[lymphocytosis]] and low glucose level.<ref name=":0" /><ref name=":1" />


**
==== Synovial fluid analysis ====
[[Synovial fluid]] analysis may reveal [[lymphocytic]] predominate with [[granulocyte]] count which  does not generally exceed 15,000 cells/microL and low [[glucose]] levels.<ref name=":0" /><ref name=":1" />


==Gallery==
==Gallery==
Line 109: Line 119:
==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:Bacterial diseases]]
[[Category:Occupational diseases]]
[[Category:Zoonoses]]
[[Category:Infectious disease]]
[[Category:Biological weapons]]
[[Category:Disease]]
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Up-To-Date]]
[[Category:Pulmonology]]
[[Category:Hepatology]]
[[Category:Rheumatology]]
[[Category:Nephrology]]
[[Category:Emergency medicine]]
[[Category:Infectious disease]]

Latest revision as of 20:44, 29 July 2020

Brucellosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Brucellosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Principles of diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT Scan

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Brucellosis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Brucellosis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Brucellosis laboratory findings

CDC on Brucellosis laboratory findings

Brucellosis laboratory findings in the news

Blogs on Brucellosis laboratory findings

Directions to Hospitals Treating Brucellosis

Risk calculators and risk factors for Brucellosis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Danitza LukacVishal Devarkonda, M.B.B.S[3]

Overview

The diagnosis of brucellosis can be confirmed by either a positive bacterial culture or a positive titer of anti-brucella antibodies on serological testing.

Laboratory Findings

Laboratory findings of brucellosis include the following:[1][2][3][4][5][6][7][8][9][10][11][12][13]

Laboratory findings in Brucellosis
Blood Complete blood count Complete Blood Count may reveal:
ESR Normal or raised
CRP Normal or raised
Liver function test Liver function test may reveal:
Culture
Serological tests Serological Tests
  • There are two types of serological tests, based on:
  • For a diagnosis to be made using serology, two serum samples are required:
    • The first serum sample should be taken when a person is acutely ill (≤7 days after symptom onset)
    • The second serum sample should be drawn 2-4 weeks later to check for a rise in antibodies (a fourfold or greater rise in antibodies would bean an individual is positive for brucellosis).
    • If submission of paired sera is not possible, a probable diagnosis can be made with a single serum sample.
  • Brucella microagglutination test (BMAT)
  • Rose Bengal
    • Rose bengal has a positive predictive value is approximately 99% for patients with acute and chronic brucellosis.
    • Rose bengal measures IgM and IgG antibodies.
  • 2-mercaptoethanol (2-ME)
  • Antihuman globulin (Coombs)
    • Used in chronic brucellosis patients with negative seroagglutination because they have IgG non-agglutinating antibodies.
  • Indirect enzyme linked immunosorbent assay (ELISA)
  • Dipstick assays
    • New and promising, based on the binding of Brucella IgM antibodies, and found to be simple, accurate and rapid.
  • Brucellacapt test
    • A single-step immunocapture assay for the detection of total anti-Brucella antibodies, is an increasingly used adjunctive test when resources permit.
Molecular tests PCR
  • PCR is a fast and specific diagnostic tool to confirm the diagnosis of brucellosis
  • Many varieties of PCR have been developed (e.g. nested PCR, realtime PCR and PCR-ELISA) and found to have superior specificity and sensitivity in detecting both primary infection and relapse after treatment.
  • Unfortunately, these have yet to be standardized for routine use, and some centres have reported persistent PCR positivity after clinically successful treatment, fuelling the controversy about the existence of prolonged chronic brucellosis.[14][15][16][17]

Tissue Biopsy

Liver and lymph node biopsy may reveal non-caseating granuloma.[2][4]

CSF analysis

CSF analysis may reveal lymphocytosis and low glucose level.[2][4]

Synovial fluid analysis

Synovial fluid analysis may reveal lymphocytic predominate with granulocyte count which does not generally exceed 15,000 cells/microL and low glucose levels.[2][4]

Gallery

References

  1. ↑ 1.0 1.1 Brucellosis. CDC. http://www.cdc.gov/brucellosis/clinicians/bacterial-isolation.html. Accessed on February 4, 2016
  2. ↑ 2.0 2.1 2.2 2.3 Brucellosis "Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson, Joseph Loscalzo"Harrison's Principles of Internal Medicine, 19e Accessed on December 9th, 2017
  3. ↑ Colmenero JD, Reguera JM, Martos F, Sánchez-De-Mora D, Delgado M, Causse M; et al. (1996). "Complications associated with Brucella melitensis infection: a study of 530 cases.". Medicine (Baltimore). 75 (4): 195–211. PMID 8699960
  4. ↑ 4.0 4.1 4.2 4.3 Mantur BG, Amarnath SK, Shinde RS (2007). "Review of clinical and laboratory features of human brucellosis.". Indian J Med Microbiol. 25 (3): 188–202. PMID 17901634
  5. ↑ Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). "Brucellosis.". N Engl J Med. 352 (22): 2325–36. PMID 15930423.
  6. ↑ Dean AS, Crump L, Greter H, Hattendorf J, Schelling E, Zinsstag J (2012). "Clinical manifestations of human brucellosis: a systematic review and meta-analysis". PLoS Negl Trop Dis. 6 (12): e1929. doi:10.1371/journal.pntd.0001929. PMC 3516581. PMID 23236528.
  7. ↑ Young EJ (1995). "Brucellosis: current epidemiology, diagnosis, and management.". Curr Clin Top Infect Dis. 15: 115–28. PMID 7546364
  8. ↑ Aygen B, Doganay M, Sumerkan B, et al. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med Malad Infect 2002; 32:485.
  9. ↑ Zamani A, Kooraki S, Mohazab RA, Zamani N, Matloob R, Hayatbakhsh MR; et al. (2011). "Epidemiological and clinical features of Brucella arthritis in 24 children". Ann Saudi Med. 31 (3): 270–3. doi:10.4103/0256-4947.81543. PMC 3119967. PMID 21623056.
  10. ↑ Mousa AM, Bahar RH, Araj GF, Koshy TS, Muhtaseb SA, al-Mudallal DS; et al. (1990). "Neurological complications of brucella spondylitis.". Acta Neurol Scand. 81 (1): 16–23. PMID 2330811
  11. ↑ Pappas G, Bosilkovski M, Akritidis N, Mastora M, Krteva L, Tsianos E (2003). "Brucellosis and the respiratory system.". Clin Infect Dis. 37 (7): e95–9. PMID 13130417. doi:10.1086/378125
  12. ↑ Herrick JA, Lederman RJ, Sullivan B, et al. Brucella arteritis: clinical manifestations, treatment, and prognosis. Lancet Infect Dis 2014; 14:520.
  13. ↑ Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME; et al. (2007). "Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations". PLoS Med. 4 (12): e317. doi:10.1371/journal.pmed.0040317. PMC 2222927. PMID 18162038.
  14. ↑ 14.0 14.1 Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). "Brucellosis". N Engl J Med. 352 (22): 2325–36. doi:10.1056/NEJMra050570. PMID 15930423.
  15. ↑ Brucellosis. CDC. http://www.cdc.gov/brucellosis/transmission/index.html. Accessed on February 1, 2016
  16. ↑ Brucellosis. Wikipedia. https://en.wikipedia.org/wiki/Brucellosis. Accessed on January 29, 2016
  17. ↑ Brucelosis. Wikipedia. https://es.wikipedia.org/wiki/Brucelosis. Accessed on February 2, 2016
  18. ↑ 18.00 18.01 18.02 18.03 18.04 18.05 18.06 18.07 18.08 18.09 18.10 18.11 "Public Health Image Library (PHIL)".

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Brucellosis_laboratory_findings&oldid=1635526"